Navigation Links
ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
Date:5/13/2008

ion. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated several clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN(R), a specific CCR9 antagonist, is currently in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX140, which targets the CCR2 receptor, is currently in Phase I and may subsequently be developed for diseases such as vascular restenosis, Type 2 diabetes and/or multiple sclerosis, and CCX354, a CCR1 antagonist in Phase I, is being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx is privately held. For more information, please refer to http://www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Go Healthy Initiates Additional Clinical Tests on Cholesterade
2. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
5. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
6. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
7. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
8. BrainCells Inc. Initiates Phase 2 Clinical Trial with BCI-540 for Depression with Anxiety
9. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Decision Resources Group ... sclerosis (MS) patients currently treated with Biogen ... ever experienced flushing and/or gastrointestinal events while ... are currently experiencing these side effects, signifying ... medical management of such events. In the ...
(Date:7/22/2014)... 22, 2014 BiologicTx ® today announced ... 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary ... July 9 at the Miami Transplant Institute, located at ... Kidney Paired Donation (KPD) is ... for kidney transplant with one another due to incompatible ...
(Date:7/22/2014)... SCHOFIELD, Wis. , July 22, 2014 /PRNewswire/ ... and marketer of over-the-counter (OTC) medicinal and healthcare ... corporate sponsor of Operation Troop Aid. ... said Russell Mitchell , CEO and Chairman ... men and women in combat zones experience migraines ...
Breaking Medicine Technology:Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 2Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted 3BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 2PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages 3
... Md., April 11, 2011 Vanda Pharmaceuticals Inc. ... Novartis Pharmaceuticals Corporation, an affiliate of Vanda,s sublicensor ... to evaluate the long-acting injectable (or depot) formulation ... study that will evaluate the safety and pharmacokinetic ...
... 11, 2011 PAREXEL International Corporation (NASDAQ: ... provider, and the Parenteral Drug Association (PDA) ... Putting Theory into Practice, written to help companies ... is being placed on biopharmaceutical companies to be accountable ...
Cached Medicine Technology:Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 2Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt® 3PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market 2PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market 3PAREXEL Expert Serves as Lead Author and Editor of Definitive Resource on Quality by Design (QbD), Aimed at Maximizing Product Quality and Speeding Treatments to Market 4
(Date:7/22/2014)... -- Autoimmune disorders may share certain pathogenic mechanisms with ... University (GW) researcher Linda Kusner, Ph.D. , published ... This paradigm shifting work shows that the very same ... also expressed in cells that produce autoimmune diseases. ... Neurology at the GW School of Medicine and Health ...
(Date:7/22/2014)... Latin American Conference on Lung Cancer (LALCA 2014) will ... Peru. , Lung Cancer is still the leading cause ... Building on the success of the previous conferences in ... will discuss the science and advances in the treatment ... and Latin America in particular. , With tobacco being ...
(Date:7/22/2014)... 2014 Ticket Down is a reliable ... at Fedex Field in Landover, MD. There has never been ... of international soccer. After the success of the American national soccer ... alive and well. One way that fans of the world’s sport ... with the 2014 Guinness International Champions Cup. The tournament will kick ...
(Date:7/22/2014)... Angeles, CA (PRWEB) July 22, 2014 ... the way in providing resources, educational tools and recognition ... tell the stories of prevention, treatment and recovery. On ... BLACK BOX will spotlight some of these resources with ... Health Services Administration helpline and treatment website at the ...
(Date:7/22/2014)... July 22, 2014 The market for ... past few years, owing to novel medical indications created ... in the aging societies where physical appearance is extremely ... one player, current competitors, new companies and technologies are ... biosimilar BoNTs will put the price of 1st-gen products ...
Breaking Medicine News(10 mins):Health News:New research finds pathogenic connection between autoimmune disorders and cancer 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 2Health News:Manchester United vs. Inter Milan Tickets Fedex Field Landover: Ticket Down Slashes Ticket Prices for Inter Milan ManU International Champions Cup Match in Washington, DC 3Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4
... Retinal snapshots could help identify with precision people at ... They say their technique is cheap enough to be ... caused by brain cell death due to bleeding from ... year in the Asia alone. , , ...
... a molecule which may harm the brain areas involved in ... disease - the doctor has to rely on the clinical ... a chemical called dopamine - which controls muscle activity - ... slowly die as the condition progresses. What kills these cells?// ...
... meat, cheese and whole milk may be at increased ... stomach. The rates of two types of cancer--gastric cardia ... past 30 years. To investigate potential links between these ... and dietary factors, Dr. Susan T. Mayne from Yale ...
... that cells exposed to high doses of iron are more responsive ... oxygen by red blood cells and iron deficiency is a relatively ... with a poor diet. That is why many breakfast cereals are ... this important mineral.// ,But too much iron might be ...
... bad for health. ,It seems that smokers have a much ... disease in their blood. The discovery could help explain why ... than non-smokers. ,Paraoxonase is a enzyme which helps ... vessels. A team of Swiss researchers examined 367 people with ...
... blood fats, unless it is combined with moderate ... heart disease risk by lowering levels of cholesterol, ... a low-fat diet is often a high-carbohydrate diet ... And it's becoming evident that a high-carbohydrate diet ...
Cached Medicine News:Health News:All the more bad, 2
Baby Weitlaner retractor, blunt, 4"....
Daubenspeck sharp curette, 8....
MRI curette, 8.5" overall length....
9.5" overall length, 4.5" handle....
Medicine Products: